While the antitumor activity of sEH and EP4 inhibition has yet to be evaluated in humans, this approach to inflammation resolution may allow for the restoration and maintenance of proresolving processes in between cycles of cytotoxic cancer therapies. This evidence concerns the gene EPHX2 and cancer.